Jobs and Careers

Senior Director Medical Affairs - HEOR

South San Francisco, United Statesfull_timeVerifiedPosted 29 Jun 2026

💰 $385,000/yr($263,000/yr – $385,000/yr)

About the role

About Us

Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.

It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.

Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.

At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families, we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic—leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn, we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.

These values are the foundation of our work, empowering us to make a real difference, every day.

Job Overview

The Senior Director Medical Affairs - Health Economics & Outcomes Research (HEOR) generates and delivers the economic and value evidence behind Kardigan's cardiovascular portfolio. The role is hands-on where it matters most (directly analyzing real-world cost, utilization, and economic outcomes from claims and linked data), while directing and critically appraising the economic models and evidence synthesis that build on that analysis, and producing the payer-facing value evidence that supports market access from development through the post-launch lifecycle. The position turns value and access priorities into finished deliverables (i.e., cost and resource-use analyses that are run directly, plus health economic models, evidence syntheses, and value dossiers it scopes, directs, and quality-assures) and partners closely with Clinical Development, Commercial, Epidemiology, Data Science / Applied ML, and Business Development.

Essential Duties and Responsibilities

Value-Evidence Planning & Prioritization

Scope the cost and utilization analyses, economic models, and evidence syntheses each program needs across development and launch, and sequence them against value and access milestones.

Prioritize the value and access questions that most affect payer, provider, and health-system decisions, and convert them into concrete analysis and deliverable plans.

Real-World Cost, Utilization & Outcomes Analysis

Personally execute costing, resource-use, and economic-outcomes analyses on claims and linked clinical–claims data, applying unit costs and valuation methods to estimate cost-of-illness, cost consequences, and budget impact for target populations.

Analyze utilization and economic outcomes (i.e., hospitalization and 30/90-day readmissions [DRG-level and condition-related], treatment and procedure costs, and pre-/post-procedure care such as AVR/TAVR) to produce the cost inputs, offsets, and economic endpoints that feed models and value claims.

Build the direct- and indirect-cost picture from the data, scoping economic and utilization endpoints (and clinical outcomes only insofar as they drive cost).

Health Economic & Decision-Analytic Modeling

Scope, specify, and own the portfolio's economic models (i.e., cost-effectiveness and cost-utility [Markov, microsimulation, discrete-event simulation, or decision-tree], budget-impact, and cost-of-illness) including structure, assumptions, a